A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 3.7% in the morning session after the company announced positive top-line results from a late-stage study of its lymphoma drug, Monjuvi/Minjuvi (tafasitamab). The Phase III trial, called frontMIND, tested the drug as a first-line treatment for adults with a type of cancer known as diffuse large B-cell lymphoma (DLBCL). The study successfully met its main goal, showing a statistically meaningful improvement in how long patients lived without their disease getting worse. Based on these strong results, Incyte planned to submit a supplemental biologics license application to the FDA in the first half of 2026 to seek approval for this expanded use.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Monday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the rest of the immuno-oncology stocks fared in Q3.
